跳至主要内容
临床试验/NCT00004759
NCT00004759已完成3 期

Phase III Randomized, Double-Blind Study of Methylprednisolone by 24- Versus 48-Hour Infusion Versus Tirilazad for Acute Spinal Cord Injury

National Institute of Neurological Disorders and Stroke (NINDS)0 个研究点目标入组 497 人开始时间: 1991年12月1日最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
497

研究概览

简要总结

OBJECTIVES:

I. Compare the efficacy and safety of 24- versus 48-hour infusion of methylprednisolone (MePRDL) versus tirilazad for patients with acute spinal cord injury.

II. Compare neurologic recovery following 24- and 48-hour MePRDL infusions.

详细描述

PROTOCOL OUTLINE:

This is a randomized, double-blind study. Patients are stratified by participating institution.

Patients are randomly assigned to 1 of 3 treatment groups within 6 hours of injury. Treatment begins within 2 hours of randomization.

One group receives a 24-hour methylprednisolone (MePRDL) infusion: a loading dose followed in 45 minutes by a 23-hour continuous infusion. A placebo for tirilazad is also administered.

A second group receives the same MePRDL loading dose but the continuous infusion is maintained for 48 hours. A placebo for tirilazad is also administered.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
14 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •PROTOCOL ENTRY CRITERIA:
  • •-Disease Characteristics--
  • •Acute spinal cord injury; diagnosis confirmed by study physician using National Acute Spinal Cord Injury Study neurologic exam
  • •Glasgow Coma Score greater than 9
  • •Randomization within 6 hours of injury required; treatment must begin within 8 hours of injury
  • •No root involvement only; no cauda equina only
  • •-Prior/Concurrent Therapy--
  • •Methylprednisolone bolus (20-40 mg/kg) prior to hospital admission allowed
  • •-Patient Characteristics--
  • •Hematopoietic: No hematologic contraindication to protocol therapy
  • •Cardiovascular: No vascular contraindication to protocol therapy
  • •Other: No diabetes; No gunshot wound; No gastrointestinal bleeding; No life-threatening co-morbidity; No other medical contraindication to protocol therapy; No pregnant women; No patients under indictment or incarcerated; No conditions that would complicate follow-up, e.g.: out-of-state residency or illegal alien status

排除标准

  • 未提供

研究者

相似试验

招募中
不适用
Methylprednisolone Versus Dexamethasone in Pediatric Caudal BlockCaudal Block
NCT05717374Mansoura University80
进行中(未招募)
不适用
Phase II Study of High-dose Methylprednisolone and Rituximab in Previously Treated Patients with High Risk Chronic B Lymphocytic Leukemia - High-dose Methylprednisolone and Rituximab in High Risk B-CTreated high-risk chronic B lymphocytic leukemia.MedDRA version: 9.1Level: LLTClassification code 10003947Term: B-Lymphocytic, CLL (Kiel Classification) recurrentMedDRA version: 9.1Level: LLTClassification code 10003948Term: B-Lymphocytic, CLL (Kiel Classification) refractory
EUCTR2007-001818-16-LTVilnius University Hospital Santariskiu Clinics50
进行中(未招募)
不适用
Cyclic Oral Methylprednisolone Trial in Multiple Sclerosisprogressive multiple sclerosisMedDRA version: 13.1Level: PTClassification code 10053395Term: Progressive multiple sclerosisSystem Organ Class: 10029205 - Nervous system disorders
EUCTR2010-024561-43-DKScleroseklinikken, Rigshospitalet30
已完成
2 期
Methylprednisolone in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome in Covid-19SARS-CoV InfectionSevere Acute Respiratory Syndrome (SARS) Pneumonia
NCT04343729Fundação de Medicina Tropical Dr. Heitor Vieira Dourado416
撤回
2 期
Effects and Safety of Infusion of Low-Doses of Methylprednisolone in Early ALI and ARDS in ChildrenAcute Lung InjuryAcute Respiratory Distress Syndrome
NCT01757899Universidade Federal do Rio de Janeiro
Methylprednisolone Given by 24-Hour or 48-Hour... | 临床试验